The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions, medical conditions where patients need treatment ...

VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today ...

VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...

HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals Inc. research and ratings by Barron's. View PCSA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a ...

HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug Administration ...

The latest price target for Processa Pharmaceuticals (NASDAQ:PCSA) was reported by HC Wainwright & Co. on September 2, 2025. The analyst firm set a price target for $1.00 expecting PCSA to fall to ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after ...

The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023.